A phase II, open-label, uncontrolled, single center study to evaluate safety and immunogenicity of a surface antigen, inactivated influenza vaccine Ph.Eur, formulation 2007-2008, when administered to non-elderly adult and elderly subjects.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2012
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 29 Aug 2007 New trial record.